PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors

Kinases such as MEK are attractive targets for novel therapy in cancer, including acute myeloid leukaemia (AML). Acquired and inherent resistance to kinase inhibitors, however, is becoming an increasingly important challenge for the clinical success of such therapeutics, and often arises from mutati...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Amanda M., Zhang, Christine R.C., Cristino, Alexandre S., Grady, John P., Fink, J. Lynn, Moore, Andrew S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791388/
https://www.ncbi.nlm.nih.gov/pubmed/31645898
http://dx.doi.org/10.18632/oncotarget.27206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791388/
https://www.ncbi.nlm.nih.gov/pubmed/31645898
http://dx.doi.org/10.18632/oncotarget.27206

Ejemplares similares